top of page
when-is-best-to-star.jpg

Biodiversity & Environmental Offset

Screen_Shot_2022-08- (1).png

Biodiversity Conservation

Join us in the unified agreements leading to successful implementation to protect and conserve indigenous knowledge and support a sustainable model for biodiversity protection of the indigenous land for the production of native plants. We are setting the foundation to uphold the standards of global conservation, for ibogaine policy.

 

Sign the protocols with us and announce the calls on the international communities to support the indigenous communities to secure the lands and protect their cultures and medicinal plants.

 

Conservation comes with a progressive society, by conserving the indigenous traditions,

and working with the ancestral knowledge of our universal entheogenic medicinal healing.

Biodiversity Conservation and Access for Benefit Sharing (ABS)

Join us in the unified agreements leading to successful implementation to protect and conserve indigenous knowledge and support a sustainable model for biodiversity protection of the indigenous land for the production of native plants. We are setting the foundation to uphold the standards of global conservation, for ibogaine policy.

​

 

Sign the protocols with us and announce the calls on the international communities to support the indigenous communities to secure the lands and protect their cultures and medicinal plants.

​

 

Conservation comes with a progressive society, by conserving the indigenous traditions, and working with the ancestral knowledge of our universal entheogenic medicinal healing.

​

Knowledge Recovery Fund International and Biodiversity and Carbon Credit for ESG valuation for Environmental Offset

​

KRFI’s economist works to build partnership in the access for benefit sharing of IP through royalties of 1% to the Private Public Sector Partnership Program for Countries observing the global partnership and the Knowledge Recovery Fund International Technical Team for the Corporate offset protocol and technology exploration.

​​​

Contact our experts in Biodiversity and Carbon Credit Sustainability Assesssment and Access for Benefit Sharing -IP Private Public Sector Partner

 

Become Partner in the Consortium for KRFI for Bioidversitty + Carbon ESG and beyond 

​

www.krfi.org/membership

Access for Benefit Sharing -IP Principles

Currently there are coroporate entities are most likely for global private public sector partners:

  1. Atai Life Sciences

    • 1 Bm Life Science company in NYC., USA and Berlin, Germany based commercial enterprise currently in MHRA,  UK ibogaine  CTA in Phase 1 and completiton 

    • Decision-makers (executive leadership) can sign onto unified CTMS governance, data-sharing, reporting.

    • Potentially can integrate into a drug-supply-chain security platform, especially for clinical-grade ibogaine / API.

    • For CT (clinical trials) reporting, atai likely has internal clinical operations / CRO partners of over 8 enteogens and psychedelics area.

    • DemeRx / Deborah Mash holds key "noribogaine' patents, they are a critical intellectual property stakeholder.

  2. Psyence BioMed / PsyLabs

    • Control of raw material supply chain (ibogaine from natural source in Africa) via PsyLabs — makes them very strategic partners to the Access for Benefit Sharing IP partner .

    • Leadership (Psyence executives, PsyLabs CEO) could be stakeholders in supply chain governance.

    • Ibogaine currently under UNCBD top list for ABS-IP products and UNODC, Interpol listing for drug trafficking listing, the national private public sector is awaiting PPP ABS-IP partnerrship because supply chain traceability is critical (especially for plant-derived psychedelics), PsyLabs would be a valuable node in a drug supply chain security platform.

  3. Soneira Biotech

    • As a synthetic-ibogaine firm, they are likely to tightly control IP and compound production.

    • Given their funding from Sergey Brin / Catalyst4, they have strong financial backing and could be a major sponsor.

    • Their leadership (management + scientists) would probably be open to participating in CTMS governance, data reporting, and informed supply chain platforms.

    • Given the novel chemistry (analogs, cardiac-safety designs), they may be especially interested in robust regulatory tracking (CT, safety, manufacturing).

  4. Clearmind Medicine

    • They have combination therapy IP; they could sponsor clinical trials, especially combination therapy trials.

    • Their R&D leaders can participate in governance, CTMS, regulatory reporting.

    • As a clinical-stage biotech, they will need secure and compliant API supply — so alignment with a supply chain security platform is plausible.

  5. ICEERS

    • As a nonprofit research organization, they are more “mission-driven” rather than strictly commercial.

    • Their leadership (scientific) can contribute to clinical-ethics committees, trial design, patient/advocacy voice.

    • However, they may be less able to commit to platform ownership (e.g., Hyperledger reporting), but can partner meaningfully.

  6. Green Cross Essential Therapeutics  LLC.

    • With Original PhytoStan - CA, Brazil holdings for the NDA Inc by Howard Lotsof, and Bob Sisko Rand IIp holder witth key original patents, with new botanical drug DMF, ODT, and Prodrug formulation enhanced to reduce the QT prolongation, they are a critical intellectual property stakeholder.

    • Their leadership should be included in strategic governance to ensure IP-aligned development, especially for API supply, reporting, and regulatory oversight.

    • They could act as sponsor (or co-sponsor) in trials, or as IP partner in alliances with KRFI Questors Technology as CRO for the CTMS, Reporting  Hyperledger, Drug Supply Chain Security Hyperledger, and Access for Benefit Sharing - IP Hyperledger as PPP partner.

  7. Texas Consortium (State + University + Hospital + Drug Developer)

    • This is a major public funding source, with strong governance.

    • The university hospital involved will likely manage CTMS, IRB, clinical operations.

    • The private drug-developer partner (once identified) will be crucial for supply chain and regulatory governance.

    • The state (Texas) could mandate reporting practices, making them a powerful stakeholder for any data-sharing or drug-supply-chain platform.

    • ​

Risks / Challenges to Consider for Governance & CTMS Integration for Ibogaine and Psychedelics Clinical Trial Grants and PPP global parttnership

​

  • Regulatory Risk: Ibogaine has known cardiac safety issues, so any clinical governance needs to be robust.

  • Supply Chain Traceability: For plant-derived ibogaine, provenance, extraction, purity are critical. Integrating with a Hyperledger-based chain would make sense, but will require buy-in from the API producer (e.g., PsyLabs) and the drug developer.

  • Intellectual Property: IP is fragmented (e.g., DemeRx holds patents, Soneira is developing analogs, atai has its own patents). Governance needs to navigate these.

  • Funding / Matching: For large-scale trials (like the Texas $50M), private match is needed. The unnamed drug developer in Texas’s public-private consortium will matter.

  • Trial Infrastructure: Clinical trial management will require experienced CRO / academic partners; governance will need to ensure data integrity, reporting, audit trails, safety monitoring.

bottom of page